Dupilumab efficacy in uncontrolled, moderate-to-severe asthma with self-reported chronic rhinosinusitis

<p><strong>Background</strong> Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for IL-4 and IL-13 signaling, key drivers of type 2 inflammation. In the phase 3 study (NCT02414854), add-on dupilumab 200 mg/300 mg every 2 weeks, versus placebo, sign...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Maspero, JF, Katelaris, CH, Busse, WW, Castro, M, Corren, J, Chipps, BE, Peters, AT, Pavord, ID, Ford, LB, Sher, L, Rabe, KF, Rice, MS, Rowe, P, Lu, Y, Harel, S, Jagerschmidt, A, Khan, A, Kamat, S, Pirozzi, G, Amin, N, Ruddy, M, Graham, NMH, Mannent, L, Teper, A
Formato:	Journal article
Idioma:	English
Publicado em:	Elsevier 2019

Dupilumab efficacy in uncontrolled, moderate-to-severe asthma with self-reported chronic rhinosinusitis

Registros relacionados